Press Releases May 27, 2026 04:00 PM

MannKind to Present at Jefferies Global Healthcare Conference

MannKind CEO to participate in Jefferies Global Healthcare Conference fireside chat discussing company innovations and strategies.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
MNKD

MannKind Corporation announced that CEO Michael Castagna will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The presentation will be webcast live and recorded versions will be available online. MannKind is focused on developing innovative treatments for chronic diseases, including diabetes and pulmonary conditions, leveraging drug-device combination technologies.

MannKind to Present at Jefferies Global Healthcare Conference
MNKD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • MannKind’s CEO will be presenting at a major healthcare industry conference, providing visibility into company strategy and developments.
  • The company focuses on cardiometabolic and orphan lung diseases, addressing unmet needs in diabetes, pulmonary hypertension, and fluid overload.
  • MannKind leverages its expertise in drug-device combinations to develop patient-centric therapies aimed at improving chronic disease management.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.


Risks

  • Market and regulatory acceptance of MannKind’s innovative therapies remains uncertain, potentially impacting future commercial success.
  • Competition in the biopharmaceutical sector for chronic and rare diseases is intense, posing challenges to market penetration and revenue growth.
  • Technological and operational risks exist in the development and commercialization of drug-device combinations, which could delay or limit product adoption.

More from Press Releases

Kandi Technologies’ Subsidiary Enters into Exclusive Five-Year Partnership with Greentown Community Business Group Jul 7, 2026 Aptera Motors Receives EPA Certificate of Conformity for 2026 Launch Edition, Marking a Key Regulatory Milestone Jul 7, 2026 Kosmos Energy to Host Second Quarter 2026 Results and Webcast on August 3, 2026 Jul 7, 2026 Shell second quarter 2026 update note Jul 7, 2026 Kayan Announces US-Regulated ATS Sets August 3, 2026 Listing Date Jul 6, 2026